•Plasma lipopolysaccharide-binding protein (LBP), a proxy for intestinal permeability, relates to clinicopathological and immunological disease activity in inflammatory bowel disease patients at diagnosis and during disease course
•Precision inflammation targeting via myeloperoxidase mediated antioxidant melanin nanomedicines for chronic inflammation therapy
•Longitudinal SARS-CoV-2 mRNA vaccine immunogenicity in inflammatory bowel disease in relation to anti-TNF therapy and age: a prospective cohort study
•Mitochondria-targeted phosphorescent iridium (III) probes for turn-on imaging of selenocysteine dynamics during inflammatory bowel disease
•Contemporary outcomes and restorative pathways following colectomy for inflammatory bowel disease: a tertiary centre cohort from Aotearoa New Zealand
